EULAR Conference Highlights Promising Advances in Lupus Treatments
The European Alliance of Associations for Rheumatology (EULAR) conference in London showcased new trial data for potential treatments of systemic lupus erythematosus (SLE), a chronic autoimmune disease. Notable developments include Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran. These drugs, which are in various stages of clinical trials, have shown promising results in reducing disease activity and improving patient outcomes. Nipocalimab, for instance, demonstrated significant disease activity reduction in the JASMINE study, while dapirolizumab pegol showed reduced flares in the PHOENYCS GO trial. 
